Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest EU Innovative Health Initiative Funding Round Offers Ample Opportunity For Medtech

Executive Summary

The EU Innovative Health Initiative has opened its doors to a new round of applicants, with opportunities for the medtech sector to form research groups with other stakeholders and work on projects including novel diagnostics and digital mental health tools.

You may also be interested in...

How To Jump Aboard The New EU Innovative Health Initiative Train And Where It Is Heading

For MedTech Europe’s Patrick Boisseau, the newly launched Innovative Health Initiative is a real “game changer.” In this interview, he explains how companies should get involved in cross-sectoral medtech/pharma projects that will revolutionize European healthcare innovation.

Medtech Connect Episode 2: What Is The European Health Data Space?

In this episode of new podcast series Medtech Connect, Medtech Insight’s regulatory writer for Europe, Eliza Slawther, interviews Alexander Olbrechts, director for digital health at the European trade body MedTech Europe, to find out more about the proposed European Health Data Space initiative and what it means for the medical device industry.

EU Borderline Product Court Ruling Puts Tricky ‘Negative Burden Of Proof’ On Manufacturers

When is a borderline drug/device product a medical device? Only when the manufacturer can prove that is definitely not a medicine, according to a new EU Court of Justice ruling. Expert medtech regulatory lawyer Erik Vollebregt outlines his main criticisms of this judgment.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts